… for worsening heart failure. Secondary outcomes included cardiovascular mortality, heart failure hospitalizations alone … heart failure, reduced ejection fraction, HFrEF, mortality, hospitalization, cardiac glycosides, guideline-directed therapy …

… the discovery of effective therapies while reducing the time, … billion to bring a single therapy to market. Drug repurposing … changes in biomarkers that track heart failure progression. To strengthen the … mean faster access to therapies for patients and lower …

… that includes investigational therapeutics for congestive heart failure, limb-girdle muscular … -fda-regenerative-medicine-advanced-therapy-designation-for-parkinsons-disease … -investigational-gene-therapy/;. Accessed September 2025 …

… multiple recent FDA-approved therapies; however, these therapies are most effective when … with equitable access to effective therapies, will be essential to improving … Black and Hispanic individuals with heart failure. JAMA Cardiol. Published online September …

… insights to develop novel cardiopulmonary therapies, announced that the European Patent … chief executive officer of Tenax Therapeutics. “The European patent is … pulmonary hypertension (PH) associated with heart failure with preserved ejection fraction (PH …

… Enbumyst; Corstasis Therapeutics), an outpatient diuretic therapy indicated for the … including specalist offices, outpatient heart failure clinics, and integrated delivery … REFERENCES 1. Corstasis Therapeutics. Corstasis Therapeutics Announces FDA Approval of …

For people at elevated risk of ventricular arrhythmias, sustaining high-normal potassium concentration levels lead to improved outcomes in a new randomized controlled investigation of 1,200 people with implanted cardioverter defibrillators (ICDs). The …

… people with heart failure with preserved ejection fraction (HFpEF) and heart failure with … based therapies using insights from Get With The Guidelines® - Heart Failure data … Improving care for people experiencing heart failure with preserved or mildly reduced …

… edema associated with congestive heart failure (CHF), liver disease, … 1 Announced by Corstasis Therapeutics on September 15, 2025 … application.2 Corstasis Therapeutics presented the results … response and advancing ambulatory heart failure care?. Heart Fail Rev …

… insights to develop novel cardiopulmonary therapies, today announced that the European … pulmonary hypertension (PH) associated with heart failure with preserved ejection fraction (PH … with PH-HFpEF. About Tenax Therapeutics Tenax Therapeutics, Inc. is a Phase …